Table 1.
Clinical characteristics of patient cohorts undergoing serial magnetic resonance imaging (MRI)
| Cohort (n=83) | Active surveillance (n=54) | Diagnosis (n=29) | p | |
|---|---|---|---|---|
| Age | ||||
| Median (IQR) | 64.3 (59.0–69.8) | 65.7 (60.2–69.9) | 63.0 (58.4–67.4) | 0.401 |
| Prostate volume | ||||
| Median (IQR) | 48.0 (33.0–75.0) | 48.5 (33.8–74.3) | 47.0 (30.0–89.0) | 0.397 |
| PSA (ng/mL) | ||||
| Median (IQR) | 7.0 (5.0–10.0) | 5.8 (4.2–7.3) | 9.6 (7.9–12.5) | <0.001 |
| PSA density | ||||
| Median (IQR) | 0.12 (0.07–0.22) | 0.10 (0.06–0.15) | 0.22 (0.11–0.30) | 0.017 |
| Number of lesions on first scan | ||||
| 0 | 17 (20.5) | 2 (22.2) | 5 (17.2) | 0.515 |
| 1 | 29 (34.9) | 20 (37.0) | 9 (31.0) | |
| 2 | 30 (36.1) | 17 (31.5) | 13 (44.8) | |
| 3 | 5 (6.0) | 4 (7.4) | 1 (3.4) | |
| 4 | 1 (1.2) | 1 (1.9) | 0 (0) | |
| 5 | 1 (1.2) | 0 (0) | 1 (3.4) | |
| MRI observation time (years) | ||||
| Median (IQR) | 1.87 (1.14–2.74) | 1.89 (1.18–2.74) | 1.84 (1.03–2.63) | 0.936 |
IQR: interquartile range; PSA: prostate-specific antigen.